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Methods. We identiﬁed 381 patients with squamous cell HNCA treated between 1992 and 2011 at the University Hospital of
Salamanca. We included demographic, clinical and tumor characteristics. We performed univariate and multivariate analysis
to examine overall survival from ﬁve or more years from diagnosis. We used the nonparametric method of Kaplan–Meier and
proportional hazards model of Cox (method: Forward stepwise). A p value less than or equal to 0.05 was considered statistically
signiﬁcant. The analysis was performed using SPSS 12.0.
Results. The 85.8% of the cases were male. The mean age was 64.14 years (S.D. = 12.27). 76% were advanced cases (stages III
and IV). The most common site was the larynx with 39.1%. The median follow-up of the cohort was 19.6 months (interquartile
range=27.9). Patients considered long survivors were 28.7%. In univariate and multivariate analysis, the comorbidity of other
vascular disease (HR= .142, p= .028), alcohol consumption (HR= .241, p= .020), the disease-free interval (HR= .903, p= .0001), ini-
tial treatment response (HR=10.038, p= .010), local recurrence (HR=5.436, p= .033) and the staging (HR=2.754, p= .004) were
associated with long-survivor status.
Conclusions. Most variables found in the univariate analysis associated with the state of surviving long follow-up, have been
reported in other studies that have set up times of less than ﬁve years. The most signiﬁcant variables in the multivariate model
were time tracking disease free (protective factor) and response to initial treatment (risk factor).
http://dx.doi.org/10.1016/j.rpor.2013.03.277
Prior, synchronous and metachronous malignancies in patients with head and neck cancer
P. Soria Carreras1, C. Gil Restrepo2, J. Velasquez Zapata3, K. Matskov2, M. Blanco2, A. Nieto Palacios2,
A. Rodriguez Gutierrez2, O. Alonso Rodriguez2, V. Macias Hernanadez2, C. Cigarral 2, L. Pérez Romasanta2
1 Hospital Universitario Salamanca, Oncologia Radioterápica
2 Hospital Universitario Salamanca
3 Oncólogo Radioterápico, Doctorando Universidad Salamanca
Introduction. Malignant tumors of the head and neck are associated with second primary malignancies by common etiology
(tobacco, alcohol, virus), usually in lung and upper aerodigestive tract and is published a frequency of up to 25% of patients.
Methods. We analyzed the incidence of other malignancies (either previous, synchronous or metachronous to cancer diagnosis
of head and neck) in patients referred to our department from 2007 to 2011 for head and neck cancer treatment.
Results. During the period of ﬁve years, have been referred to our department, 352 patients with head and neck cancer diag-
nosis. Median follow-up of 32 months (9–72 months). 47 patients (13.16% of total) had experienced another previous tumor,
the most common: ORL 36%, 12% basal cell carcinoma and 6% each of the following: lung. hematologic, colon, prostate and
squamous cell carcinoma of skin. Synchronous tumors ORL cancer diagnosis in 8 patients (2.25%), in 6 cases of lung cancer
and one case of cancer of the esophagus and thyroid. After treatment and cure of head and neck tumors, 19 patients (5.32%)
developed a second malignancy. Median onset: 12 months (range 1–46 months). Lung tumor in 37% of cases, 2nd tumor ORL:
21%; esophagus 16% and the remaining of cases, only one patient (5.2%) each other: breast, sigma, kidney, colon and penis. We
have only had three cases of emergence of a third tumor, two cases of ORL and one tumor of the esophagus. Time of onset of
8–35 months.
Conclusion. The development of second and third malignancies in patients diagnosed with cancer of head and neck cancer is a
widely known fact. In our series, our results are somewhat lower than those published in the literature and currently do not
reach the 3% annual 2nd tumors.
http://dx.doi.org/10.1016/j.rpor.2013.03.278
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The malignant tumor of the external auditory duct and middle ear is a low incidence disease so literature review of these tumors
is quite complicated due to heterogeneity in therapeutic strategies proposed. We report the case of a patient of 44 years old
consulting with right otalgia and otorrhea for several months. On examination external auditory duct lesion whose biopsy was
reported as squamous cell carcinoma. Seen on CT mass of 2.6 cm×2 cm destroying alveolar process until the right maxillary
sinus. No lymphadenopathy. In PET, hypermetabolic lesion in the rightmaxillary bone and inﬁltration of adjacent soft tissueswith
SUV of 8.9. Stage IE-A. Chemotherapy is discarded. Received 3D radiotherapy (RT) on tumor lesion reaching a total dose of 41.4Gy
fractionation of 1.8Gy/session, 5h/week by 6MV photon energy from the linear accelerator. Complete clinical response at the end
of RT treatment with excellent tolerance (G2 mucositis). Squamous cell carcinoma is the most common tumor in this location
and have a worse prognosis for rapid growth and tendency to regional metastases. It usually presents as a granulomatous area
occupies part or whole canal, with areas of ulceration, otorrhagia, otorrhea and pain. Hearing loss, facial paralysis progressive,
cervical lymphadenopathy and injury of cranial nerves are signs of locally advanced disease and poor prognosis. The combination
of surgery and RT is the treatment most likely to be offered within the survival prognosis with these tumors. Radiation therapy
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has no impact on local control when bone involvement or resection margins were positive, but if the resection was complete,
most authors recommend the use of these two treatment arms.
http://dx.doi.org/10.1016/j.rpor.2013.03.279
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Objective. To analyze the acute toxicities in rRT with curative intent in CCC.
Methods. Retrospective review of 21 patients reirradiated due to CCC with curative intent between May 2004 and December 2012.
All were treated by 3D technique with 6 MV photons. On 1st fractionation RT with 2Gy/day and rRT with 1.8Gy/day. Toxicity was
collected according to RTOG scale.
Results. Initial treatment was concomitant cisplatin-based chemoradiation in 9 patients, surgery plus adjuvant RT in 7, neoad-
juvant RTCT in 3 and exclusive RT in 2. In the second disease were 11 local recurrences objectiﬁed, 7 nodal recurrences and 3
seconds tumors. We chose concomitant RTCT with different chemotherapy regimens in 11 patients, surgery plus adjuvant RTCT
in 7 patients and surgery plus adjuvant RT in 3. The average time between the end of the ﬁrst irradiation and rRT was 24 months,
one case less than six months. The mean dose of the 1st RT was 67.7Gy and 64.3Gy in rRT. The PTV in the 1st irradiation was
256.8 cc and 119.3 cc of the rRT. The acute toxicities occur in higher incidence in the rRT. Radiodermatitis was presented in 25% in
the 1 st RT (grade I 25%, 50% Grade II, 25% Grade III) and 50% by rRT (grade II 37%, 63% Grade III). Odynophagia occurred in 31.3%
in the 1st RT (grade I 20%, 60% grade II, grade III 20%) and 43.8% in rRT (grade II 57.1%, 42.9% grade III). Mucositis was presented
in 37.5% in the 1st RT (grade I 33%, 33% grade II, grade III 33%) and 25% by rRT (grade I 25%, 50% grade II, 25 grade III %). Note that
it has made no toxic death by rRT. To date, the average follow-up is 15.4 months. Currently 7 patients are alive, free of disease 4.
Conclusions. We believe that the rRT in CCC is acceptably tolerated and should be considered as a therapeutic option in selected
cases.
http://dx.doi.org/10.1016/j.rpor.2013.03.280
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Purpose. To analyze a retrospective review of the outcomes in patients who underwent re-irradiation (re-RT), after recurrent or
new primary head and neck cancer (HN) at our institution.
Methods and materials. 27 patients with HN cancer were treated with re-RT at our center, from April 2004 to November 2012,
consisting of 23 men and 4 women. Median age was 64 years. Tumor sites of recurrence or new primary included oral cavity
(n=7), larynx (n=5), hypopharynx (n=3), oropharynx (n=1), skull base (n=2), neck (n=5), paranasal sinuses (n=1), parotid (n=1),
skin (n=1) and esophagus (n=1). Median prior RT dose was 66Gy, and median re-RT dose was 59.7Gy. All patients, except one,
received chemotherapywith re-RT. IMRTwas used as re-RT technique in 17 cases (63%), and stereotactic body radiotherapy (SBRT)
in 5 (18.5%).
Results. At the present moment, 15 patients (55.5%) were alive; 10 of them, with no evidence of disease. The median follow-up was
of 17 months. Re-RT control and disease control rates were 63% and 48.1%, respectively. Mean survival since re-RT achieved 22.46
months, whereas mean local progression-free survival (LPFS) was 16.77. The probability of local control, one year after re-RT,
was 67%, and after 2 years, 54%. The most frequent acute toxicity was dermatitis (≥G2 in 40.7%). 3 patients (11.1%) presented
osteonecrosis requiring either hyperbaric oxygen ormedical treatment. Severe late toxicity, such as carotid blow-up,was reported
in one case. One patient died during re-RT and concurrent chemotherapy treatment due to sepsis.
Conclusions. Recurrence and/or appearance of new primary HN tumors lead to a variety of possible treatments, being re-RT a
feasible option that can obtain acceptable results, as demonstrated by our data, although late toxicity risks should be considered.
Therefore, patients who undergo re-RT must be carefully selected, in order to assure beneﬁt from re-RT.
http://dx.doi.org/10.1016/j.rpor.2013.03.281
